Plasma and peritoneal concentration following continuous infusion of cefotaxime in patients with secondary peritonitis

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 3, 2009, Pages 564-567

  Seguin, Philippe ^a   Verdier, Marie Clémence ^a   Chanavaz, Charles ^a   Engrand, Charlotte ^a   Laviolle, Bruno ^a   Donnio, Pierre Yves ^a   Mallédant, Yannick ^a  

^a UNIVERSITÉ DE RENNES 1   (France)

Author keywords

Critically ill patients; High performance liquid chromatography; Human; Protein binding

Indexed keywords

CEFOTAXIME; DEACETYLCEFOTAXIME; METRONIDAZOLE; NORADRENALIN;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL PERITONITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG PERITONEAL FLUID LEVEL; ENTEROBACTERIACEAE; FEMALE; GRAM NEGATIVE BACTERIUM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LOADING DRUG DOSE; MALE; MINIMUM INHIBITORY CONCENTRATION; PERITONEAL FLUID; SEPTIC SHOCK;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ASCITIC FLUID; CEFOTAXIME; CRITICAL ILLNESS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PERITONITIS; PLASMA;

EID: 60649092333     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn522     Document Type: Article

References (10)

1. Seguin P, Laviolle B, Chanavaz C et al. Factors associated with multidrug-resistant bacteria in secondary peritonitis: Impact on antibiotic therapy. Clin Microbiol Infect 2006; 12: 980-5.
2. Solomkin JS, Mazuski JE, Baron EJ et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003; 37: 997-1005.
3. MacGowan AP, Bowker KE. Continuous infusion of β-lactam antibiotics. Clin Pharmacokinet 1998; 35: 391-402.
4. Mohr JF, Wanger A, Rex JH. Pharmacokinetic/pharmacodynamic modeling can help guide targeted antimicrobial therapy for nosocomial Gram-negative infections in critically ill patients. Diagn Microbiol Infect Dis 2004; 48: 125-30.
5. Neu HC. Antibacterial activity of desacetylcefotaxime alone and in combination with cefotaxime. Rev Infect Dis 1982; 4: S374-8.
6. Mazuski JE, Sawyer RG, Nathens AB et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: Evidence for the recommendations. Surg Infect 2002; 3: 175-233.
7. Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: A review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 2005; 44: 1009-34.
8. Buijk SE, Gyssens IC, Mouton JW et al. Perioperative pharmacokinetics of cefotaxime in serum and bile during continuous and intermittent infusion in liver transplant patients. J Antimicrob Chemother 2004; 54: 199-205.
9. Heim KL, Halstenson CE, Comty CM et al. Disposition of cefotaxime and desacetyl cefotaxime during continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 1986; 30: 15-9.
10. Karjagin J, Lefeuvre S, Oselin K et al. Pharmacokinetics of meropenem determined by microdialysis in the peritoneal fluid of patients with severe peritonitis associated with septic shock. Clin Pharmacol Ther 2008; 83: 452-9.